Get the Stockscreener App
5.28
0.00%
0.01
Trisalus Life Sciences Inc stock is traded at $5.28, with a volume of 58,882.
It is up +0.00% in the last 24 hours and up +22.84% over the past month.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
See More
Previous Close:
$5.27
Open:
$5.23
24h Volume:
58,882
Relative Volume:
0.12
Market Cap:
$324.50M
Revenue:
$45.15M
Net Income/Loss:
$-39.23M
P/E Ratio:
-2.8868
EPS:
-1.829
Net Cash Flow:
$-18.93M
1W Performance:
-5.56%
1M Performance:
+22.84%
6M Performance:
+10.48%
1Y Performance:
+15.82%
1-Day Range:
$5.18
$5.445
1-Week Range:
$5.18
$5.91
52-Week Range:
$2.20
$7.95
Trisalus Life Sciences Inc Stock (TLSI) Company Profile
Name
Trisalus Life Sciences Inc
Sector
Industry
Phone
415 336 8917
Address
6272 WEST 91ST AVENUE, WESTMINSTER
Compare TLSI vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLSI
Trisalus Life Sciences Inc
|
5.27 | 324.50M | 45.15M | -39.23M | -18.93M | -1.829 |
ABT
Abbott Laboratories
|
110.12 | 192.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
332.32 | 130.11B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
90.64 | 116.83B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
51.55 | 75.11B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.80 | 52.80B | 6.30B | 1.07B | 1.09B | 1.8406 |
Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Initiated | Lake Street | Buy |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-11-24 | Initiated | ROTH MKM | Buy |
| Oct-25-24 | Initiated | Northland Capital | Outperform |
| Sep-16-24 | Initiated | Oppenheimer | Outperform |
| May-30-24 | Initiated | Canaccord Genuity | Buy |
View All
Trisalus Life Sciences Inc Stock (TLSI) Latest News
TriSalus Life Sciences (NASDAQ:TLSI) Cut to "Sell" at Wall Street Zen - MarketBeat
TriSalus Life Sciences Inc (TLSI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Trisalus Life Sciences at Canaccord Genuity: growth bets build By Investing.com - Investing.com Nigeria
Trisalus Life Sciences at Canaccord Genuity: growth bets build - Investing.com
TriSalus Life Sciences (TLSI) Advances 2.87% as Shares Hold Above $5.45 SupportETH Profile - dars.gov.et
TriSalus Life Sciences earnings missed by $0.01, revenue topped estimates - Investing.com Canada
TriSalus Life Sciences (TLSI) Stock Surges As Losses Deepen Behind Strong Margins - Sahm
Securities Fraud Investigation Into TriSalus Life Sciences Inc - The National Law Review
TriSalus Life Sciences, Inc. (TLSI) stock price, news, quote and history - Yahoo Finance UK
TriSalus Life Sciences (NASDAQ:TLSI) Posts Quarterly Earnings Results, Meets Expectations - MarketBeat
TriSalus Life Sciences, Inc. Revenue Breakdown – NASDAQ:TLSIW - TradingView
TriSalus Life Sciences Q2 Earnings Call Highlights - MarketBeat
Price to earnings forward of TriSalus Life Sciences, Inc. – NASDAQ:TLSIW - TradingView
TriSalus Life Sciences Inc (TLSI) (Q2 2026) Earnings Call Highlights: New CMS G-code Expands ... - Yahoo Finance
Earnings call transcript: TriSalus tops Q2 revenue forecast, stock slips after hours - Investing.com
Price to sales forward of TriSalus Life Sciences, Inc. – NASDAQ:TLSIW - TradingView
TriSalus Life Sciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
TLSI: Q2 revenue rose to $11.4M, with expanded OBL reimbursement and strong growth outlook - TradingView
TriSalus Q2 2026 Earnings: Gross Margin Rises as Operating Loss Widens - TradingKey
TriSalus Life Sciences, Inc. 2026: Revenue $11.41M, EPS ($0.16) — 10-Q Summary - TradingView
TriSalus Life Sciences Reports Second Quarter 2026 Results - marketscreener.com
Inside TriSalus Life Sciences (NASDAQ: TLSI) Q2 2026 performance - Stock Titan
TriSalus Life Sciences, Inc. Maintains Revenue Guidance for the Full Year 2026 - marketscreener.com
TLSI: Q2 revenue up 1.7% to $11.4M, gross margin 88%, and 2026 guidance reaffirmed at $54–$57M - TradingView
Earnings To Watch: TriSalus Life Sciences Inc (TLSI) Q2 2026 -- GF Value Sees 20% Upside - Yahoo Finance
TriSalus Life Sciences Inc expected to post a loss of 15 cents a shareEarnings Preview - TradingView
TriSalus Life Sciences (TLSI) Stock Forum and Discussion - Moomoo
TriSalus Life Sciences (TLSI) to Post Earnings on Thursday - MarketBeat
TriSalus CEO and CFO to Join Canaccord Fireside Chat Aug. 12 - Stock Titan
TriSalus Life Sciences Inc (TLSI) Cash Flow - TradingKey
TriSalus Life Sciences Inc (TLSI) Valuation: PE, PB & Fair Value Analysis - TradingKey
TriSalus Life Sciences Inc (TLSI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TriSalus Life Sciences Inc (TLSI) Balance Sheet - TradingKey
First Light Asset Management LLC Invests $20.27 Million in TriSalus Life Sciences, Inc. $TLSI - MarketBeat
TriSalus Life Sciences Inc (TLSI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TLSI Q1 2026 Earnings: Strong EPS Surprise as Company Focuses on PipelineLong-Term Guidance - dars.gov.et
TriSalus Life Sciences Inc (TLSI) Income Statement - TradingKey
TLSI|TriSalus Life Sciences Inc|Price:4.360|Chg%:+0.040 - TradingKey
TriSalus Life Sciences (TLSI) Q1 2026 Earnings: EPS Surprises to the Upside as Stock SlipsEarnings Acceleration Picks - dars.gov.et
TLSI|TriSalus Life Sciences Inc|Price:4.220|Chg%:-0.050 - TradingKey
TriSalus Life Sciences, Inc. Revenue Breakdown – NASDAQ:TLSI - TradingView
TriSalus Life Sciences Inc (TLSI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TriSalus Life Sciences Initiates PREDICTT Clinical Trial - Medical Product Outsourcing
Lobbying Update: $90,000 of TRISALUS LIFE SCIENCES lobbying was just disclosed - Quiver Quantitative
Press Release: TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call - Moomoo
TriSalus Life Sciences to host Q2FY26 financial results call - scanx.trade
TriSalus sets Aug. 6 webcast for second-quarter results - Stock Titan
TriSalus Life Sciences (TLSI) Edges Higher as Stock Tests Key Resistance LevelsLow Risk Entry Stocks - dars.gov.et
Price to sales forward of TriSalus Life Sciences, Inc. – NASDAQ:TLSI - TradingView
TriSalus Life Sciences, Inc. (TLSI) reports Q1 loss, lags revenue estimates - MSN
TLSIW SEC FilingsTriSalus Life Sciences Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Trisalus Life Sciences Inc Stock (TLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Trisalus Life Sciences Inc Stock (TLSI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wahlstrom Mats | Director |
May 15 '26 |
Buy |
2.53 |
60,000 |
151,800 |
147,555 |
| Stansky Michael P | Director |
May 15 '26 |
Buy |
2.50 |
410,000 |
1,025,000 |
1,240,722 |
| Stansky Michael P | Director |
May 15 '26 |
Buy |
2.50 |
200,000 |
500,000 |
399,698 |
| Szela Mary T | CEO and President |
May 15 '26 |
Buy |
2.59 |
39,682 |
102,776 |
1,065,215 |
| Patience David | Chief Financial Officer |
May 15 '26 |
Buy |
2.43 |
7,100 |
17,253 |
275,757 |
| Gordon Gary B. | Director |
May 15 '26 |
Buy |
2.46 |
10,000 |
24,600 |
72,510 |
| Devlin Jodi | Chief of Clinical Operations |
Mar 12 '26 |
Sale |
4.09 |
1,772 |
7,247 |
97,637 |
| Devlin Jodi | Chief of Clinical Operations |
Mar 11 '26 |
Sale |
4.13 |
1,162 |
4,799 |
99,409 |
| Devlin Jodi | Chief of Clinical Operations |
Mar 16 '26 |
Sale |
4.12 |
273 |
1,125 |
97,364 |
| Cox Bryan F. | Chief of Research |
Mar 12 '26 |
Sale |
4.09 |
1,467 |
6,000 |
163,994 |
2.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):